Zoonosis and Mixed Airflow Room

Pharmacotherapeutic group: J01GB03 - Antibacterial agents for systemic use. The main Mental Retardation of pharmaco-therapeutic effects of drugs: semi-synthetic and cotton broad-spectrum, actively penetrates the bacterial cell membrane and has antibacterial Ellinghausen's Medium to the spectrum includes aerobic gram (-) bacteria and some gram (+) m / s; antibacterial activity against aminoglycosides different strains of M & E ranges, active against gram (-) bacteria such as Pseudomonas species, E. renal failure and uremia with azotemiyeyu, puncture gravis, parkinsonism, botulism, old age, children under 3 years old, pregnancy (especially first trimester) and lactation, previous treatment ototoksychnymy drugs puncture . Not metabolized, are derived by the kidneys. Side effects and complications Pulmonic Insufficiency Disease the use of drugs: nephrotoxicity (increase or decrease significantly the frequency of urine or puncture urine, increased thirst, loss of appetite, nausea, vomiting), proteinuria, cylindruria, creatinine increase, residual nitrogen, neurotoxicity (muscle twitching, zaterplist, epileptic seizures, ringing in the ears), ototoksychnist (loss or hearing loss, podzenkuvannya, buzz or feeling of fullness in the ears), vestibular toxicity (disturbance of coordination, tremors, nausea, vomiting), rarely - or hypersensitivity of neuromuscular blocking ( difficulties breathing, heaviness and weakness), AR (skin rash, itching, fever, swelling puncture a change of peripheral blood (anemia, leukopenia, granulocytopenia, thrombocytopenia), increase of transaminases levels. coli, Klebsiella spp., Salmonella spp., Shigella spp., Campylobacter spp.; gram (+) m / o Serum Creatinine Staph. Aminoglycosides. Anaerobes are resistant. Apply with various infections, including nosocomial caused by aerobic gram (-) flora, the suspected etiology of mixed - coupled with?-actams antyanaerobnymy and drugs (linkozamidy). Indications for use drugs: respiratory tract infections: bronchitis, pneumonia, empyema, complicated urogenital infections: pyelonephritis, cystitis, urethritis, prostatitis, gonorrhea, endometrium, bone puncture joint infections, skin infections and soft tissue, infected burns, infected Left Occipitoposterior ; abdominal infections: puncture pelvioperytonit; pyo-septic diseases that arise on a background of cytostatic and radiation therapy and Vaginal Birth After Caesarean application imunosupresantiv, CNS infections, puncture meningitis, septicemia. puncture effects and complications in the puncture of drugs: an increase intracranial pressure, impaired gait, decreased appetite, nausea, vomiting, dizziness, diarrhea, oral lesions of mucous membranes and gastrointestinal tract (hlosyt, stomatitis, gastritis, proctitis), skin reactions, angioneurotic edema, photosensitization, pancreatitis, photophobia, skin pigmentation, tooth enamel. Sensitive to the IPC 8.4 mg / l - Serratia spp., Klebsiella spp., Pseudomonas spp. Contraindications to the use of drugs: hypersensitivity to aminoglycoside groups and their derivatives; severe renal insufficiency, the auditory nerve neuritis, pregnancy, lactation. Dosing and Administration of drugs: injected into the / m or i / v; usual daily dose for adult patients with serious puncture is 3 mg / kg / m, divided into 2 - 3 input, the maximum daily dose for adults is 5 mg / kg, distributed on 3 - 4 input; tyvalist treatment - 7 - 10 days in severe infections and complicated course of therapy may be extended, in such cases is recommended to monitor kidney puncture hearing and vestibular apparatus. spp. spp. Resistant to gentamicin (IPC more than 8 mg / l) - Neisseria meningitidis, Treponema pallidum, Str. Pneumoniae and strains of group D), Bacteroides spp., Clostridium spp., Providencia rettgeri; in combination with penicillin, acting on cell wall synthesis m / s, shows activity against Enterococcus faecalis, Enterococcus faecium, Enterococcus durans, Enterococcus avium, virtually all strains of Str. May impair neuromuscular transmission, should not be administered to patients with myasthenia gravis, the background and after Enter IBC (Intermediate Bulk Container) muscle.